Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4158-4165

  Chatzistamou, I ^a   Schally, A V ^a   Nagy, A ^a   Armatis, P ^a   Szepeshazi, K ^a   Halmos, G ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; GONADORELIN; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FEMALE; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; DOXORUBICIN; ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033765579     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. LH-RH analogues. Their impact on the control of tumorigenesis
2. Evolution in the treatment of advanced breast cancer
3. Hypothalamic and other peptide hormones
4. Chemotherapy targeted to hormone receptors on tumors
5. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers
6. Targeted cytotoxic luteinizing hormone-releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis
7. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs
8. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers
9. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
10. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
11. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines
12. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer
13. LH-RH analogs with cytotoxic radicals
14. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin
15. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
16. Computerized determination of growth kinetic curves and doubling times from cells in microculture
17. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice
18. Ligand: A versatile computerized approach for characterization of ligand binding systems
19. Growth of human breast cancer cells inhibited by luteinizing hormone-releasing hormone agonist
20. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists
21. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studies
22. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone
23. Apoptosis versus necrosis: Which should be the aim of cancer therapy?